12.87
+0.12(+0.94%)
Currency In USD
| Previous Close | 12.75 |
| Open | 12.74 |
| Day High | 13.06 |
| Day Low | 12.55 |
| 52-Week High | 13.1 |
| 52-Week Low | 2.88 |
| Volume | 295,712 |
| Average Volume | 418,180 |
| Market Cap | 461.45M |
| PE | 0.95 |
| EPS | 13.61 |
| Moving Average 50 Days | 7.8 |
| Moving Average 200 Days | 5.22 |
| Change | 0.12 |
If you invested $1000 in BioAge Labs, Inc. (BIOA) since IPO date, it would be worth $702.89 as of December 14, 2025 at a share price of $12.87. Whereas If you bought $1000 worth of BioAge Labs, Inc. (BIOA) shares 6 months ago, it would be worth $2,938.36 as of December 14, 2025 at a share price of $12.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
GlobeNewswire Inc.
Dec 04, 2025 2:00 PM GMT
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 Hig
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 9:30 PM GMT
EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of hu
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of hu